Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stock Position in Hologic, Inc. $HOLX

Key Points

• Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in Hologic, Inc. by 20.3% during the first quarter, owning 52,214 shares worth approximately $3.225 million at the end of the reporting period.
• Several analysts upgraded their ratings on Hologic, with the price target increasing from $72.00 to $87.00 by Royal Bank of Canada, indicating positive sentiment in the market.
• Hologic's recent quarterly earnings beat expectations, reporting $1.08 EPS and $1.02 billion in revenue, reflecting a 1.2% year-over-year growth.

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 20.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 52,214 shares of the medical equipment provider's stock after purchasing an additional 8,826 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Hologic were worth $3,225,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Farther Finance Advisors LLC boosted its holdings in shares of Hologic by 22.3% during the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after purchasing an additional 335 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Hologic by 116.6% in the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock valued at $594,000 after acquiring an additional 5,172 shares during the last quarter. Brevan Howard Capital Management LP lifted its holdings in Hologic by 85.5% in the fourth quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock valued at $1,401,000 after acquiring an additional 8,960 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in Hologic by 1.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock valued at $1,980,000 after acquiring an additional 528 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its holdings in Hologic by 4.5% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 17,945 shares of the medical equipment provider's stock valued at $1,108,000 after acquiring an additional 767 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on HOLX shares. Raymond James Financial reiterated an "outperform" rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Stephens decreased their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. UBS Group upped their price objective on Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a report on Thursday, July 31st. Morgan Stanley upped their price objective on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Finally, Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and upped their price objective for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Hologic currently has an average rating of "Moderate Buy" and an average price target of $78.00.

Hologic Trading Up 1.4%

NASDAQ:HOLX traded up $0.94 during trading hours on Wednesday, reaching $68.76. 1,890,938 shares of the stock were exchanged, compared to its average volume of 2,791,684. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The business has a 50-day moving average of $65.71 and a two-hundred day moving average of $62.50. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $15.29 billion, a price-to-earnings ratio of 28.53, a PEG ratio of 2.44 and a beta of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the prior year, the company earned $1.06 earnings per share. The company's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.